Tag: #clinicaltrials

Sham-controlled trial finds pulmonary vein isolation no better than sham for atrial fibrillation quality of life at six months

A multicentre sham-controlled trial in Europe published in The Lancet found PVI didn’t improve AF-related quality of life versus sham at six months.

#atrialfibrillation, #catheterablation, #cardiology, #clinicaltrials

MHRA details pilot to cut Phase 1 clinical trial review to 14 days by end of 2026

MHRA outlines a staged pilot to reduce first-assessment times for eligible Phase 1 trials in healthy volunteers to 14 days by end-2026, with tight eligibility and limited slots.

#mhra, #clinicaltrials, #uk, #phase1

Radioligand 177Lu-PSMA-617 Delays Radiographic Progression in PSMA-Positive Hormone-Sensitive Metastatic Prostate Cancer, Phase 3 Trial Shows

Phase 3 PSMAddition trial found 177Lu‑PSMA‑617 added to hormonal therapy reduced risk of radiographic progression in PSMA‑positive mHSPC.

#prostatecancer, #radioligandtherapy, #pluvicto, #clinicaltrials

Pfizer’s Phase 3 Lung Cancer Drug Misses Overall Survival Goal; Stronger Trend in Second‑Line Patients

Pfizer's Phase 3 lung cancer trial of sigvotatug vedotin missed its overall survival goal; company sees a stronger trend in second‑line patients.

$PFE, #pfizer, #oncology, #lungcancer, #clinicaltrials

UK Phase I trial finds AI-designed coronavirus vaccine candidate safe and elicits cross-reactive immune responses

Phase I UK trial: an AI-designed DNA vaccine for sarbecoviruses was safe in 39 adults and induced cross-reactive immune responses, but not proof it protects.

#covid-19, #vaccine, #clinicaltrials, #ai

Interim phase 3: Sacituzumab tirumotecan plus pembrolizumab improves PFS in PD-L1–positive advanced NSCLC

Interim phase 3 data: adding sacituzumab tirumotecan to pembrolizumab improved progression-free survival versus pembrolizumab alone in PD‑L1+ advanced NSCLC; OS immature, toxicity higher.

$MRK, #lungcancer, #pembrolizumab, #sacituzumabtirumotecan, #clinicaltrials